Zydus to develop typhoid and shigellosis vaccine
** Zydus Lifesciences (BSE: 532321) announced a collaboration with the Gates Foundation to develop a novel combination vaccine targeting shigellosis and typhoid. The project, slated to commence in March 2025, aims to protect children under five from these deadly enteric diseases. Zydus will leverage its WHO prequalified Typhoid conjugate vaccine (ZyVacTM TCV) and a Shigella Vaccine from its partner in this endeavor. Typhoid fever causes an estimated 135,000–230,000 deaths each year while Shigella accounts for about 212,000 deaths. The collaboration seeks to provide a cost-effective and sustainable solution where childhood immunization schedules are becoming increasingly crowded. The company has stated it is committed to innovation that addresses critical gaps through solutions that have a sustainable global impact.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime